Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Invitae | RCV001351724 | SCV001546218 | pathogenic | not provided | 2024-01-04 | criteria provided, single submitter | clinical testing | This sequence change replaces methionine, which is neutral and non-polar, with valine, which is neutral and non-polar, at codon 219 of the ALPL protein (p.Met219Val). This variant is present in population databases (rs772432010, gnomAD 0.02%). This missense change has been observed in individual(s) with clinical features of hypophosphatasia (PMID: 24022022; Invitae). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. ClinVar contains an entry for this variant (Variation ID: 1047062). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt ALPL protein function with a positive predictive value of 95%. Experimental studies are conflicting or provide insufficient evidence to determine the effect of this variant on ALPL function (PMID: 24022022). For these reasons, this variant has been classified as Pathogenic. |
Baylor Genetics | RCV003469587 | SCV004194319 | likely pathogenic | Adult hypophosphatasia | 2023-11-18 | criteria provided, single submitter | clinical testing | |
Natera, |
RCV001825976 | SCV002094065 | uncertain significance | Hypophosphatasia | 2021-10-14 | no assertion criteria provided | clinical testing |